• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CDTX alert in real time by email
    SC 13G 1 tm2430061d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Cidara Therapeutics, Inc.

    (Name of Issuer)

     

    Common stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    171757206

    (CUSIP Number)

     

    November 26, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 171757206 Page 2 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,129,097 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,129,097 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,129,097 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of pre-funded warrants (the “Pre-Funded Warrants”) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The Pre-Funded Warrants contain a provision (the “Beneficial Ownership Blocker”) which precludes exercise of the Pre-Funded Warrants to the extent that, following exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

     

    (3)This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2024; (ii) 3,892,274 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on November 26, 2024 (the “Private Placement”); and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 171757206 Page 3 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,129,097 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,129,097 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,129,097 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

     

    (3)This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 171757206 Page 4 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,129,097 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,129,097 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,129,097 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

     

    (3)This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 171757206 Page 5 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,129,097 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,129,097 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,129,097 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

     

    (3)This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 171757206 Page 6 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,129,097 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,129,097 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,129,097 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

     

    (3)This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 171757206 Page 7 of 17

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,129,097 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,129,097 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,129,097 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

     

    (3)This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 171757206 Page 8 of 17

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,129,097 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,129,097 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,129,097 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

     

    (3)This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 171757206 Page 9 of 17

     

    Item 1.
      (a)

    Name of Issuer

     

    Cidara Therapeutics, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    6310 Nancy Ridge Drive, Suite 101

    San Diego, CA 92121

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     
      (b)

    Address of Principal Business Office or, if none, Residence

         
        New York Office: Palo Alto Office:
           
        7 Bryant Park 3340 Hillview Avenue
        23rd Floor Palo Alto, CA 94304
        New York, NY 10018
         
      (c)

    Citizenship

         
        All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.
     
      (d)

    Title of Class of Securities

     

    Common Stock, $0.0001 par value

     
      (e)

    CUSIP Number

     

    171757206

           

     

     

     

     

    CUSIP No. 171757206 Page 10 of 17

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable
     
    Item 4. Ownership
       
      (a) Amount beneficially owned:
         
            Venrock Healthcare Capital Partners III, L.P. 1,129,097 (1)
            VHCP Co-Investment Holdings III, LLC 1,129,097 (1)
            Venrock Healthcare Capital Partners EG, L.P. 1,129,097 (1)
            VHCP Management III, LLC 1,129,097 (1)
            VHCP Management EG, LLC 1,129,097 (1)
            Nimish Shah 1,129,097 (1)
            Bong Koh 1,129,097 (1)
     
      (b) Percent of class:
         
            Venrock Healthcare Capital Partners III, L.P. 9.99% (2)
            VHCP Co-Investment Holdings III, LLC 9.99% (2)
            Venrock Healthcare Capital Partners EG, L.P. 9.99% (2)
            VHCP Management III, LLC 9.99% (2)
            VHCP Management EG, LLC 9.99% (2)
            Nimish Shah 9.99% (2)
            Bong Koh 9.99% (2)
     
      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote:
           
            Venrock Healthcare Capital Partners III, L.P. 0  
            VHCP Co-Investment Holdings III, LLC 0  
            Venrock Healthcare Capital Partners EG, L.P. 0  
            VHCP Management III, LLC 0  
            VHCP Management EG, LLC 0  
            Nimish Shah 0  
            Bong Koh 0  
     
        (ii) Shared power to vote or to direct the vote:
           
            Venrock Healthcare Capital Partners III, L.P. 1,129,097 (1)
            VHCP Co-Investment Holdings III, LLC 1,129,097 (1)
            Venrock Healthcare Capital Partners EG, L.P. 1,129,097 (1)
            VHCP Management III, LLC 1,129,097 (1)
            VHCP Management EG, LLC 1,129,097 (1)
            Nimish Shah 1,129,097 (1)
            Bong Koh 1,129,097 (1)
                 

     

     

     

     

    CUSIP No. 171757206 Page 11 of 17

     

        (iii) Sole power to dispose or to direct the disposition of:
           
            Venrock Healthcare Capital Partners III, L.P. 0  
            VHCP Co-Investment Holdings III, LLC 0  
            Venrock Healthcare Capital Partners EG, L.P. 0  
            VHCP Management III, LLC 0  
            VHCP Management EG, LLC 0  
            Nimish Shah 0  
            Bong Koh 0  
     
        (iv) Shared power to dispose or to direct the disposition of:
           
            Venrock Healthcare Capital Partners III, L.P. 1,129,097 (1)
            VHCP Co-Investment Holdings III, LLC 1,129,097 (1)
            Venrock Healthcare Capital Partners EG, L.P. 1,129,097 (1)
            VHCP Management III, LLC 1,129,097 (1)
            VHCP Management EG, LLC 1,129,097 (1)
            Nimish Shah 1,129,097 (1)
            Bong Koh 1,129,097 (1)
                 

     (1) Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

     

        VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    (2) This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 1 above.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable

     

     

     

     

    CUSIP No. 171757206 Page 12 of 17

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 171757206 Page 13 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 4, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC  
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 171757206 Page 14 of 17

     

    EXHIBITS

     

    A: Joint Filing Agreement
       
    B: Power of Attorney for Nimish Shah
       
    C: Power of Attorney for Bong Koh

     

     

     

     

    CUSIP No. 171757206 Page 15 of 17

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Cidara Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 4th day of December 2024.

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC  
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 171757206 Page 16 of 17

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of December 2024.

     

    /s/ Nimish Shah  

     

     

     

     

    CUSIP No. 171757206 Page 17 of 17

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of December 2024.

     

    /s/ Bong Koh  

     

     

     

    Get the next $CDTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDTX

    DatePrice TargetRatingAnalyst
    3/12/2025$46.00Mkt Outperform
    Citizens JMP
    1/27/2025Overweight
    Cantor Fitzgerald
    12/13/2024$34.00Outperform
    RBC Capital Mkts
    11/8/2024$33.00Buy
    Guggenheim
    8/14/2024$24.00Neutral → Buy
    H.C. Wainwright
    12/3/2021$6.00Buy
    H.C. Wainwright
    9/22/2021$9.00 → $8.00Buy
    Aegis Capital
    9/22/2021$6.25Buy → Strong Buy
    WBB Securities
    More analyst ratings

    $CDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Cidara Therapeutics with a new price target

      Citizens JMP initiated coverage of Cidara Therapeutics with a rating of Mkt Outperform and set a new price target of $46.00

      3/12/25 7:22:04 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald resumed coverage on Cidara Therapeutics

      Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight

      1/27/25 8:36:28 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital Mkts initiated coverage on Cidara Therapeutics with a new price target

      RBC Capital Mkts initiated coverage of Cidara Therapeutics with a rating of Outperform and set a new price target of $34.00

      12/13/24 7:27:23 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

      FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com

      4/16/25 8:00:46 AM ET
      $CDTX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program

      3/6/25 4:35:37 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

      SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e

      2/18/25 4:15:00 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Stein Jeffrey bought $105,680 worth of shares (8,000 units at $13.21) (SEC Form 4)

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      6/11/24 6:26:28 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

      SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here. The event will feature key opinion leaders (KOLs) Fred Hayden, MD, FACP (University of Virginia School of Medicine) and Rick Bright, PhD (Pandemic Prevention Institute, The Rockefeller Foundation), who will join company management to discuss CD388, Cidara's long-acting antiviral drug designed to revolutionize influenza pro

      5/15/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

      SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 10:00 AM ET Event: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:40 AM ET The live webcast for the presentations can be accessed in the Investors section on the Company's website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days. Cida

      5/13/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro

      5/8/25 4:15:38 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Davarpanah Nicole Negar was granted 10,000 shares, increasing direct ownership by 46% to 31,692 units (SEC Form 4)

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      5/12/25 8:40:21 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Davarpanah Nicole Negar claimed ownership of 21,692 shares (SEC Form 3)

      3 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      5/12/25 8:37:41 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President & CEO Stein Jeffrey

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      4/2/25 6:28:15 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CDTX
    SEC Filings

    See more
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/9/24 5:37:15 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/4/24 4:15:14 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/3/24 4:34:49 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Cidara Therapeutics Inc.

      EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)

      5/16/25 12:15:29 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cidara Therapeutics Inc.

      SCHEDULE 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)

      5/15/25 4:25:28 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Cidara Therapeutics Inc.

      SCHEDULE 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      5/12/25 9:04:22 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Financials

    Live finance-specific insights

    See more
    • Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro

      5/8/25 4:15:38 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Thursday, May 8, 2025Time:5:00 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conferen

      4/24/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

      - $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve

      4/24/24 4:05:00 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care